Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5:...
-д хадгалсан:
| Үндсэн зохиолч: | |
|---|---|
| Бусад зохиолчид: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Хэвлэсэн: |
2025
|
| Нөхцлүүд: | |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
| _version_ | 1849927633220927488 |
|---|---|
| author | H. Josh Jang (15206898) |
| author2 | Galen Hostetter (15053070) Alexander W. Macfarlane (15206901) Zachary Madaj (15206904) Eric A. Ross (15019395) Toshinori Hinoue (15206907) Justin R. Kulchycki (15206910) Ryan S. Burgos (15206913) Mahvish Tafseer (15206916) R. Katherine Alpaugh (15206919) Candice L. Schwebel (15206922) Rutika Kokate (15206925) Daniel M. Geynisman (15206928) Matthew R. Zibelman (15206931) Pooja Ghatalia (15206934) Peter W. Nichols (15206937) Woonbok Chung (15206940) Jozef Madzo (14923007) Noah M. Hahn (15206943) David I. Quinn (15012291) Jean-Pierre J. Issa (15109358) Michael J. Topper (15206946) Stephen B. Baylin (15045804) Hui Shen (10996894) Kerry S. Campbell (9724036) Peter A. Jones (14941116) Elizabeth R. Plimack (15044781) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | H. Josh Jang (15206898) Galen Hostetter (15053070) Alexander W. Macfarlane (15206901) Zachary Madaj (15206904) Eric A. Ross (15019395) Toshinori Hinoue (15206907) Justin R. Kulchycki (15206910) Ryan S. Burgos (15206913) Mahvish Tafseer (15206916) R. Katherine Alpaugh (15206919) Candice L. Schwebel (15206922) Rutika Kokate (15206925) Daniel M. Geynisman (15206928) Matthew R. Zibelman (15206931) Pooja Ghatalia (15206934) Peter W. Nichols (15206937) Woonbok Chung (15206940) Jozef Madzo (14923007) Noah M. Hahn (15206943) David I. Quinn (15012291) Jean-Pierre J. Issa (15109358) Michael J. Topper (15206946) Stephen B. Baylin (15045804) Hui Shen (10996894) Kerry S. Campbell (9724036) Peter A. Jones (14941116) Elizabeth R. Plimack (15044781) |
| author_role | author |
| dc.creator.none.fl_str_mv | H. Josh Jang (15206898) Galen Hostetter (15053070) Alexander W. Macfarlane (15206901) Zachary Madaj (15206904) Eric A. Ross (15019395) Toshinori Hinoue (15206907) Justin R. Kulchycki (15206910) Ryan S. Burgos (15206913) Mahvish Tafseer (15206916) R. Katherine Alpaugh (15206919) Candice L. Schwebel (15206922) Rutika Kokate (15206925) Daniel M. Geynisman (15206928) Matthew R. Zibelman (15206931) Pooja Ghatalia (15206934) Peter W. Nichols (15206937) Woonbok Chung (15206940) Jozef Madzo (14923007) Noah M. Hahn (15206943) David I. Quinn (15012291) Jean-Pierre J. Issa (15109358) Michael J. Topper (15206946) Stephen B. Baylin (15045804) Hui Shen (10996894) Kerry S. Campbell (9724036) Peter A. Jones (14941116) Elizabeth R. Plimack (15044781) |
| dc.date.none.fl_str_mv | 2025-11-25T13:08:38Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30707732 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Tables_1_from_A_Phase_II_Trial_of_Guadecitabine_plus_Atezolizumab_in_Metastatic_Urothelial_Carcinoma_Progressing_after_Initial_Immune_Checkpoint_Inhibitor_Therapy/30707732 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade Small Molecule Agents Epigenetic-targeted agents |
| dc.title.none.fl_str_mv | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5: Immunohistochemistry scores of tumorsSupplementary Table 6: FACS panel for PBMC analysisSupplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACSSupplementary Table 8: Representativeness of Study Participants</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_a3e96fe524011f0399731b1ba4e4335b |
| identifier_str_mv | 10.1158/1078-0432.30707732 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30707732 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor TherapyH. Josh Jang (15206898)Galen Hostetter (15053070)Alexander W. Macfarlane (15206901)Zachary Madaj (15206904)Eric A. Ross (15019395)Toshinori Hinoue (15206907)Justin R. Kulchycki (15206910)Ryan S. Burgos (15206913)Mahvish Tafseer (15206916)R. Katherine Alpaugh (15206919)Candice L. Schwebel (15206922)Rutika Kokate (15206925)Daniel M. Geynisman (15206928)Matthew R. Zibelman (15206931)Pooja Ghatalia (15206934)Peter W. Nichols (15206937)Woonbok Chung (15206940)Jozef Madzo (14923007)Noah M. Hahn (15206943)David I. Quinn (15012291)Jean-Pierre J. Issa (15109358)Michael J. Topper (15206946)Stephen B. Baylin (15045804)Hui Shen (10996894)Kerry S. Campbell (9724036)Peter A. Jones (14941116)Elizabeth R. Plimack (15044781)CancerTherapeutic Research and DevelopmentImmuno-oncologyClinical Research and TrialsClinical Trial ResultsGenitourinary CancersBladder cancerImmunotherapyCheckpoint blockadeSmall Molecule AgentsEpigenetic-targeted agents<p>Supplementary TablesSupplementary Table 1: Patient and tumor sample informationSupplementary Table 2: Tumor mutation burdenSupplementary Table 3: Unfiltered whole exome sequencing mutation analysisSupplementary Table 4: Filtered whole exome sequencing mutation analysisSupplementary Table 5: Immunohistochemistry scores of tumorsSupplementary Table 6: FACS panel for PBMC analysisSupplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACSSupplementary Table 8: Representativeness of Study Participants</p>2025-11-25T13:08:38ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30707732https://figshare.com/articles/dataset/Supplementary_Tables_1_from_A_Phase_II_Trial_of_Guadecitabine_plus_Atezolizumab_in_Metastatic_Urothelial_Carcinoma_Progressing_after_Initial_Immune_Checkpoint_Inhibitor_Therapy/30707732CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307077322025-11-25T13:08:38Z |
| spellingShingle | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy H. Josh Jang (15206898) Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade Small Molecule Agents Epigenetic-targeted agents |
| status_str | publishedVersion |
| title | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| title_full | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| title_fullStr | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| title_full_unstemmed | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| title_short | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| title_sort | Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy |
| topic | Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade Small Molecule Agents Epigenetic-targeted agents |